BioSpace News Archive

With intuitive operation and a new advanced peak detection algorithm, this software supports review-by-exception to improve the speed and efficiency of multi-analyte data analysis.

The award is to support a Phase 3 clinical trial to evaluate the safety and efficacy of MDR-101.

The data showed that lefitolimod can significantly improve the anti-tumor effect of checkpoint inhibitors, particularly anti-PD-1 and anti-PD-L1 antibodies, and thus prolong survival in murine tumor models.

The EC approval marks Bristol-Myers Squibb’s first pediatric indication for an Immuno-Oncology medicine in the European Union (EU) and allows for the marketing of Yervoy for this indication in all 28 Member States of the EU.

Neovasc’s outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.

CanniMed announces that it is continuing to discuss terms of a possible transaction with Aurora Cannabis Inc. (“Aurora”).

Avacen Medical announced that it is launching sales of its AVACEN 100 in Hong Kong to address the challenge of autistic spectrum disorder behavior management.

Dr. Helen Torley, president and chief executive officer, will lead the call.

Seattle Genetics, Inc. reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization for ADCETRIS (brentuximab vedotin) to include the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

Syros announced that the U.S. Patent and Trademark Office has issued two patents covering methods for stratifying patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) for treatment with SY-1425 (tamibarotene), the Company’s first-in-class selective retinoic acid receptor alpha (RARα) agonist.